Bemarituzumab (bema)+FOLFOX6 as first-line treatment in patients with FGFR2b overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer (G/ GEJC): East Asia subgroup of FIGHT final analysis
Bemarituzumab (bema)+FOLFOX6 as first-line treatment in patients with FGFR2b overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer (G/ GEJC): East Asia subgroup of FIGHT final analysis
저자
Kang, Y-K.; Qin, S.; Lee, K-W.; Oh, S. C.; Kim, I-H.; Kim, J. G.; Li, Y.; Yan, Z.; Li, J.; Bai, L-Y.; Chan, C. P. K.; Yusuf, A.; Zahlten-Kuemeli, A.; Taylor, K.; Yamaguchi, K.